Current status and future applications of cardiac receptor imaging with positron emission tomography

Nuclear Medicine Communications

Volumn 23, Issue 2, 2002, Pages 113-115

  SchAfers M ^a   Riemann, B ^a   Levkau, B ^a   Wichter, T ^a   SchAfers K ^a   Kopka, K ^a   Breithardt, G ^a   Schober, O ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC IMAGING; EDITORIAL; HEART DISEASE; HEART FUNCTION; HUMAN; ISOTOPE LABELING; LIGAND BINDING; POSITRON EMISSION TOMOGRAPHY;

ADRENERGIC BETA-ANTAGONISTS; ARTERIOSCLEROSIS; CARBON RADIOISOTOPES; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIUM; PROPANOLAMINES; RECEPTORS, NEUROTRANSMITTER; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036105919     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200202000-00001     Document Type: Editorial

References (26)

1. Tseng H, Link JM, Stratton JR, Caldwell JH. Cardiac receptor physiology and its application to clinical imaging: present and future. J Nucl Cardiol 2001; 8: 390-409.
2. Charbonneau P, Syrota A, Crouzel C, Valois JM, Prenant C, Crouzel M. Peripheral-type benzodiazepine receptors in the living heart characterized by positron emission tomography. Circulation 1986; 73: 476-483.
3. Salvetti F, Chelli B, Gesi M, et al. Effect of noise exposure on rat cardiac peripheral benzodiazepine receptors. Life Sci 2000; 66: 1165-1175.
4. Gavish M, Katz Y, Bar Ami S, Weizman R. Biochemical, physiological, and pathological aspects of the peripheral benzodiazepine receptor. J Neurochem 1992; 58: 1589-1601.
5. Syrota A, Paillotin G, Davy JM, Aumont MC. Kinetics of in vivo binding of antagonist to muscarinic cholinergic receptor in the human heart studied by positron emission tomography. Life Sci 1984; 35: 937-945.
6. Le Guludec D, Delforge J, Syrota A, et al. in vivo quantification of myocardial muscarinic receptors in heart transplant patients. Circulation 1994; 90: 172-178.
7. Le Guludec D, Cohen-Solal A, Delforge J, Delahaye N, Syrota A, Merlet P. Increased myocardial muscarinic receptor density in idiopathic dilated cardiomyopathy: an in vivo PET study. Circulation 1997; 96: 3416-3422.
8. van Waarde A, Elsinga PH, Anthonio RL, et al. Study of cardiac receptor ligands by positron emission tomography. Dordrecht, Boston, London. Kluwer Academic Publishers, 1995: 171-182.
9. Delforge J, Syrota A, Lancon JP, et al. Cardiac beta-adrenergic receptor density measured in vivo using PET, CGP 12177, and a new graphical method. J Nucl Med 1991; 32: 739-748.
10. Merlet P, Delforge J, Syrota A, et al. Positron emission tomography with 11C CGP-12177 to assess beta-adrenergic receptor concentration in idiopathic dilated cardiomyopathy. Circulation 1993; 87: 1169-1178.
11. Lefroy DC, de Silva R, Choudhury L, et al. Diffuse reduction of myocardial beta-adrenoceptors in hypertrophic cardiomyopathy: a study with positron emission tomography. J Am Coll Cardiol 1993; 22: 1653-1660.
12. Choudhury L, Rosen SD, Lefroy DC, Nihoyannopoulos P, Oakley CM, Camici PG. Myocardial beta adrenoceptor density in primary and secondary left ventricular hypertrophy. Eur Heart J 1996; 17: 1703-1709.
13. Schäfers M, Dutka D, Rhodes CG, et al. Myocardial presynaptic and postsynaptic autonomic dysfunction in hypertrophic cardiomyopathy. Circ Res 1998; 82: 57-62.
14. Wichter T, Schäfers M, Rhodes CG, et al. Abnormalities of cardiac sympathetic innervation in arrhythmogenic right ventricular cardiomyopathy: quantitative assessment of presynaptic norepinephrine reuptake and postsynaptic beta-adrenergic receptor density with positron emission tomography. Circulation 2000; 101: 1552-1558.
15. Rosen SD, Boyd H, Rhodes CG, Kaski JC, Camici PG. Myocardial beta-adrenoceptor density and plasma catecholamines in syndrome X. Am J Cardiol 1996; 78: 37-42.
16. Schäfers M, Lerch H, Wichter T, et al. Cardiac sympathetic innervation in patients with idiopathic right ventricular outflow tract tachycardia. J Am Coll Cardiol 1998; 32: 181-186.
17. Erdmann E, Schwinger R, Böhm M. Beta-blocking agents and positive inotropic agents in the therapy of chronic heart failure. J Cardiovasc Pharmacol 1990; 16: S138-S144.
18. Lüscher TF, Barton M. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation 2000; 102: 2434-2440.
19. Yanagisawa M, Kurihawa J, Kimura S, et al. Endothelin: a novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-419.
20. Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 1990; 348: 732-735.
21. B receptors in human vascular smooth muscle. J Cardiovasc Pharmacol 1993; 22: S22-S25.
22. Dagassan PH, Breu V, Clozel M, et al. Up-regulation of endothelin-B receptors in atherosclerotic human coronary arteries. J Cardiovasc Pharmacol 1996; 27: 147-153.
23. Bacon CR, Cary NRB, Davenport AP. Endothelin peptide and receptors in human atherosclerotic coronary artery and aorta. Circ Res 1996; 79: 794-801.
24. Gibson RE, Fioravanti C, Francis B, Burns HD. Radioiodinated endothelin-1: a radiotracer for imaging endothelin receptor distribution and occupancy. Nucl Med Biol 1999; 26: 193-199.
25. 11C]L-753,037: studies in mice and a dog. J Nucl Med 2001; 42: 1274-1280.
26. Johnstrom P, Aigbirhio FI, Clark JC, Downey SP, Pickard JD, Davenport AP. Syntheses of the first endothelin-A- and -B-selective radioligands for positron emission tomography. J Cardiovasc Pharmacol 2000; 36: S58-S60.